NCT01343277 - A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma | Biotech Hunter

Enrollment

579

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

April 30, 2016

Conditions

Advanced Liposarcoma or Leiomyosarcoma

Interventions

DRUG

Trabectedin

Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.

DRUG

Dacarbazine

Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.

Trial Locations (88)

Unknown

Phoenix

Tucson

Little Rock

La Jolla

Los Angeles

San Diego

San Francisco

Santa Monica

Aurora

Denver

Hartford

New Haven

Boynton Beach

Hollywood

Miami

Orlando

Tampa

Atlanta

Augusta

Savannah

Post Falls

Chicago

Naperville

Park Ridge

Peoria

Springfield

Indianapolis

Iowa City

Sioux City

Overland Park

Wichita

Louisville

Covington

Baltimore

Boston

Ann Arbor

Detroit

Lansing

Jackson

Saint Joseph

St Louis

Omaha

Henderson

Las Vegas

Lebanon

Hackensack

Morristown

Newark

Albuquerque

Johnson City

New York

Syracuse

The Bronx

Chapel Hill

Charlotte

Akron

Cleveland

Columbus

Oklahoma City

Tulsa

Portland

Philadelphia

Pittsburgh

State College

Charleston

Knoxville

Nashville

Austin

Dallas

Houston

San Antonio

Salt Lake City

Fairfax

Seattle

Morgantown

Green Bay

Milwaukee

Malvern

Randwick

Subiaco

Woolloongabba

Bahia

Barretos

Ijuí

Porto Alegre

São Paulo

Auckland

Wellington